Evaluating the cost of sustained virologic response in naïve chronic hepatitis C patients treated à la carte

Alimentary Pharmacology and Therapeutics

Volumn 26, Issue 5, 2007, Pages 705-716

  Buti, M ^a   Casado, M A ^b   Esteban, R ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b Pharmacoeconomics and Outcomes Research Iberia (PORIB)   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2A; RIBAVIRIN; VIRUS RNA;

ADULT; ARTICLE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; GENOTYPE; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; MODEL; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; STANDARD; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; COST CONTROL; DECISION TREES; DRUG THERAPY, COMBINATION; ECONOMICS, PHARMACEUTICAL; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; RIBAVIRIN; SENSITIVITY AND SPECIFICITY;

EID: 34547830868     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2007.03419.x     Document Type: Article

References (31)

1. Anonymous. National Institutes of Health Consensus Development Conference Statement: management of hepatitis C 2002 (June 10-12, 2002). Gastroenterology 2002 123:2082 99.
2. EASL. International Consensus Conference on Hepatitis C. Paris, 26-28 February 1999. J Hepatol 1999 30:956 61.
3. Alberti A, Noventa F, Benvegnu L, Boccato S, Gatta A. Prevalence of liver disease in a population of asymptomatic persons with hepatitis C virus infection. Ann Intern Med 2002 137:961 4.
4. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001 358:958 65.
5. Fried MW, Shiffman ML, Reddy RK, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002 347:975 82.
6. Hadziyannis SJ, Sette H, Morgan TR, et al. Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C. A randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004 140:346 55.
7. Dalgard O, Bjoro K, Hellum KB, et al. Treatment with pegylated interferon and ribavirin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology 2004 40:1260 5.
8. Mangia A, Santoro R, Minerva N, et al. PegInterferon alfa-2b and Ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005 352:2609 17.
9. von Wagner M, Huber M, Berg T, et al. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005 129:522 7.
10. Yu ML, Dai CY, Huang JF, et al. A randomised study of peginterferon and ribavirin for 16 vs 24 weeks in patients with genotype 2 chronic hepatitis C. Gut 2007 56:553 9.
11. Zeuzem S, Buti M, Ferenci P, et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006 44:97 103.
12. Jensen DM, Morgan TR, Marcellin P, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology 2006 43:954 60. Erratum in: Hepatology 2006; 43: 1410
13. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa2-b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003 38:645 52.
14. Wong JB, Davis G, McHutchison JG, Manns MP, Albrecht JK, International Hepatitis Interventional Therapy Group. Economic and clinical effects of evaluating rapid viral response to peginterferon alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C. Am J Gastroenterol 2003 98:2354 62.
15. Buti M, San Miguel R, Brosa M, et al. Estimating the impact of HCV therapy on the future liver-related morbidity, mortality and costs related to chronic hepatitis C. J Hepatol 2005 42:639 45.
16. Forns X, Maluenda MD, López-Labrador X, et al. Comparative study of three methods for genotyping hepatitis C virus strains in samples from Spanish patients. J Clin Microbiol 1996 34:2516 21.
17. Echevarria JM, Leon P, Avellon A. Follow-up of the prevalence of Hepatitis C virus genotypes in Spain during a nine-year period (1996-2004). Enferm Infeccy Microbiol Clin 2006 24:20 5.
18. Buti M, Casado MA, Fosbrook L, Esteban R. Financial impact of two different ways of evaluating early virological response to peginterferon alfa-2b plus ribavirin therapy in genotype 1 naïve patients with chronic hepatitis C. Pharmacoeconomics 2005 23:1043 55.
19. Jacobson IM, Brown RS, Freilich B, et al. Weight-based ribavirin dosing (WBD) increases sustained viral response (SVR) in patients with chronic hepatitis C (CHC): final results of the WIN-R study, a US community based trial. Hepatology 2005 42 (Suppl. 1 LB03.
20. Benhamou Y, Pockros P, Rodriquez-Torres M, et al. The safety and efficacy of viramidine plus pegIFN alfa-2b versus ribavirin plus pegIFN alfa-2b in therapy-naïve patients infected with HCV: phase 3 results (VISER1). J Hepatol 2006 44 (Suppl. 2 S273.
21. Buti M, Medina M, Casado MA, Wong JB, Fosbrook L, Esteban R. A cost-effectiveness analysis of peginterferon alfa-2b plus ribavirin for the treatment of naïve patients with chronic hepatitis C. Aliment Pharmacol Ther 2003 17:687 94.
22. Drummond MF, O'Brien B, Stoddart GL, Torrance GW. Costs analysis. In:Drummond MF, O'Brien B, Stoddart GL, Torrance GW, eds. Methods for the Economic Evaluation of Health Care Programmers, 2nd edn. Oxford:Oxford University Press, 1997:52 95.
23. Formann E, Steindl-Munda P, Hofer H, et al. Long-term follow-up of chronic hepatitis C patients with sustained virological response to various forms of interferon-based anti-viral therapy. Aliment Pharmacol Ther 2006 23:507 11.
24. Desmond CP, Roberts SK, Dudley F, et al. Sustained virological response rates and durability of the response to interferon-based therapies in hepatitis C patients treated in the clinical setting. J Viral Hepatol 2006 13:311 5.
25. McHutchison JG, Shiffman LM, Gordon SC, et al. Sustained virologic response (SVR) to Interferon alfa-2b +/- ribavirin therapy at 6 months reliably predicts long-term clearance of HCV at 5-year follow up. J Hepatol 2006 A744 (abstract).
26. Dienstag JL, McHutchison JG. American Gastroenterological Association Medical Position Statement on the management of hepatitis C. Gastroenterology 2006 130:225 30.
27. Brown Jr. RS, Jacobson IM, Afdhal N, et al. Differences in treatment outcome to antiviral therapy based on genotype and viral load in hepatitis C genotypes 2 and 3 in the WIN-R trial. J Hepatol 2006 A41 (abstract).
28. Buti M, Valdes A, Sanchez-Avila F, Esteban R, Lurie Y. Extending combination therapy with peginterferon alfa-2b plus ribavirin for genotype 1 chronic hepatitis C late responders: A report of 9 cases. Hepatology 2003 37:1226 7.
29. Berg T, von Wagner M, Nasser S, et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006 130:1086 97.
30. Sanchez-Tapias JM, Diago M, Escartin P, et al. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology 2006 131:451 60.
31. Shiffman MI, Pappas S, Nyberg L, et al. Peginterferon alpha 2a(Pegasys) plus ribavirin (Copegus)m for 16 or 24 weeks in patients with HCV genotype 2 and 3:Final results of the accelerate trial. J Hepatol 2006 44 (Suppl. 2 S271.